ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about ImmunoGen, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -0.8300 | -0.480 | 59 | 356 | -71 | -33 | -71 | -26 | -178 | -33 | 24 | 33 |
| 2015 | -0.7100 | -0.670 | 85 | 38 | -60 | 0.83 | -55 | 8 | -166 | 0.22 | 28 | 23 |
| 2016 | -1.6500 | -1.260 | 60 | 53 | -143 | -112 | -123 | -92 | -270 | -97 | 36 | 28 |
| 2017 | - | -1.480 | - | 41 | - | -120 | - | -100 | - | -103 | - | 30 |
| 2018 | -0.9800 | -0.850 | 115 | 156 | -96 | -117 | -55 | -88 | -197 | -71 | 33 | 41 |
| 2019 | -1.2000 | -1.230 | 53 | 51 | -167 | -163 | -153 | -146 | -330 | -156 | 36 | 35 |
| 2020 | -0.8200 | -0.770 | 82 | 114 | -122 | -86 | -65 | -58 | -185 | -70 | 38 | 49 |
| 2021 | -0.3800 | -0.450 | 132 | 92 | -66 | 30 | -19 | 74 | -135 | 67 | 38 | 67 |
| 2022 | -0.8800 | -0.740 | 108 | 74 | -222 | -174 | -217 | -156 | -220 | -157 | 116 | 56 |
| 2023 | -0.8800 | -0.050 | 108 | 357 | -222 | -73 | -217 | -179 | -220 | -180 | 116 | 78 |
| 2024 | - | 0.050 | - | 493 | - | 17 | - | -178 | - | -179 | - | 77 |
| 2025 | - | 0.348 | - | 538 | - | 104 | - | -424 | - | -538 | - | 330 |
| 2026 | - | 0.855 | - | 757 | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
ImmunoGen, Inc. can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$31.23